Citadel Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Citadel Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,100	Closed	-$321K	–	15792
2024 Q1	$321K	Buy	8,100 +800	+11%	+$23.6K	﹤0.01%	9305
2023 Q4	$139K	Buy	7,300 +5,600	+329%	+$77.8K	﹤0.01%	10505
2023 Q3	$19.5K	Sell	1,700 -600	-26%	-$7.38K	﹤0.01%	12648
2023 Q2	$23.6K	Buy	+2,300	New	+$20.7K	﹤0.01%	12587
2023 Q1	–	Sell	-1,100	Closed	-$8.09K	–	15764
2022 Q4	$8.09K	Buy	+1,100	New	+$7.03K	﹤0.01%	13771

Citadel Advisors's ALPN Position: Q2 2024 in Review

Citadel Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 142,879 shares — an estimated $5.66M sold.

Citadel Advisors first reported a position in ALPN in Q4 2015 and held it in 7 quarters. The position peaked at $16.7M in Q4 2023. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

Citadel Advisors reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 142,879 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $5.66M.
Citadel Advisors first reported a position in Alpine Immune Sciences Inc in Q4 2015 and held it in 7 quarters.
Citadel Advisors's Alpine Immune Sciences Inc position peaked at $16.7M in Q4 2023.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.